Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes major bleeding compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Time to resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Arrhythmias · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Arrhythmias · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in cardiac arrhythmias during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Death at hospital discharge · individuals with moderate to severe disease
1 finding from 1 review
Improvement of clinical status · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found